ProQR Therapeutics (PRQR) Retained Earnings (2021 - 2025)

ProQR Therapeutics' Retained Earnings history spans 4 years, with the latest figure at $29.5 million for Q4 2024.

  • For Q4 2024, Retained Earnings rose 106.84% year-over-year to $29.5 million; the TTM value through Dec 2024 reached $29.5 million, up 106.84%, while the annual FY2024 figure was $29.9 million, 106.89% up from the prior year.
  • Retained Earnings for Q4 2024 was $29.5 million at ProQR Therapeutics, up from -$431.3 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $29.5 million in Q4 2024 and bottomed at -$431.3 million in Q4 2023.
  • The 4-year median for Retained Earnings is -$375.2 million (2021), against an average of -$288.0 million.
  • The largest annual shift saw Retained Earnings dropped 11.51% in 2023 before it surged 106.84% in 2024.
  • A 4-year view of Retained Earnings shows it stood at -$363.5 million in 2021, then dropped by 6.4% to -$386.8 million in 2022, then decreased by 11.51% to -$431.3 million in 2023, then surged by 106.84% to $29.5 million in 2024.
  • Per Business Quant, the three most recent readings for PRQR's Retained Earnings are $29.5 million (Q4 2024), -$431.3 million (Q4 2023), and -$386.8 million (Q4 2022).